The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-The aim of the study was to evaluate the role of purinergic receptor P2Y, G protein-coupled 12 (P2Y12), an ADP receptor, in the development of atherosclerotic lesions. Methods and Results-Apolipoprotein E-null mice were crossed with P2y12 −/− mice to generate double knockout mice.
A therosclerosis is a chronic inflammatory disease characterized by lipid deposition and macrophage/foam cell accumulation beneath the arterial intima. The progression of atherosclerosis, from fatty streaks to more complex lesions, is driven by a variety of cell types and cytokines. [1] [2] [3] [4] Platelets are one of the crucial cell types involved in atherogenesis. Platelets are an important link between inflammation, atherogenesis, and thrombosis. As part of their role in atherogenesis, platelets interact with leukocytes, endothelial cells, and release chemokines and cytokines, leading to the infiltration of leukocytes into the vascular wall. 5, 6 Lending support to this model, some studies have shown that inhibiting plateletendothelium or platelet-leukocyte interactions, or inhibiting platelet-derived chemokine functions, can lead to decreased plaque size and improved plaque stability. [7] [8] [9] [10] [11] Despite the wide acknowledgment of atherogenesis as an inflammatory disease, the rationale underlying current therapy for atherosclerosis-related diseases is the inhibition of platelet aggregation and clotting that occurs in response to atherosclerotic lesion rupture. The ADP receptor purinergic receptor P2Y, G protein-coupled 12 (P2Y12) is abundantly expressed in platelets and smooth muscle cells (SMCs). P2Y12 plays a prominent role in amplifying platelet activation, aggregation, and thrombus formation, [12] [13] [14] and accordingly serves as an effective pharmacological target of antiplatelet therapies. Although the beneficial effects of treatment with the P2Y12 antagonist clopidogrel are assumed to be a consequence of inhibition of platelet aggregation, contributions of platelets to coagulation and thrombus formation, other benefits of clopidogrel treatment have also been observed. For example, a study by Klinkhardt et al 15 showed that patients receiving clopidogrel had lower P-selectin expression on platelets and reduced platelet-leukocyte aggregate formation. Other studies on patients with atherothrombotic diseases also demonstrated an apparent clopidogrel-induced reduction in serum levels of soluble CD40 ligand, C-reactive protein in addition to P-selectin expression, and platelet-leukocyte aggregate formation. [16] [17] [18] These studies point to the involvement of P2Y12 in atherogenesis through the regulation of the release of proinflammatory mediators from platelets, and the related leukocyte recruitment and vascular infiltration. These data might possess great clinical importance considering the wide therapeutic use of the P2Y12 inhibitor clopidogrel to treat coronary artery, peripheral vascular, and cerebrovascular diseases. Therefore, confirmation of these data may justify expanding the clinical use of clopidogrel to include prevention of atherosclerosis development assuming that P2Y12 is a significant contributor to the vascular inflammatory response.
However, studies of clopidogrel effects on plaque development and composition in murine models have provided inconsistent results, with one study observing no obvious effect 19 and others reporting an antiatherogenic property of clopidogrel resulting from an increased number of atheroprotective regulatory CD4 + CD25 + T cells. 20 It is therefore of great interest to clarify whether or not P2Y12 modulates atherogenesis in vivo. The studies described here were designed to investigate the role of P2Y12 in atherosclerosis and to delineate the underlying mechanism.
Methods

Mouse Model of Atherosclerosis, Bone Marrow Transplantation, and Quantification of Lesions
P2y12 −/− mice 14 were crossed with apolipoprotein E-null (apoE −/− ) mice (from the Model Animal Research Center of Nanjing University, Nanjing, China) to generate apoE +/− P2y12 +/mice which then were interbred to generate apoE −/− P2y12 +/+ (designed as apoE −/− ) and apoE −/− P2y12 −/− (designed as double knockout [DKO]) mice. All mice were in the C57BL/6 background. The mice were fed a highfat diet (21% fat, 0.2% cholesterol, 23% protein, and 40.5% carbohydrate purchased from Shanghai SLAC Laboratory Animal Co, Shanghai, China) for a total of 20 weeks before further analysis.
For bone marrow (BM) transplantation, 8-week-old male DKO recipient mice, pretreated with polymyxin and neomycin for 10 days, were given lethal γ-ray irradiation at total doses of 13.5 Gy split as 9+4.5 Gy (3 hours apart) using a 137Cs γ-irradiation unit (Gammacell 3000 Elan, Best Theratronics Ltd, Bristol, RI). The lethal irradiation dose was determined in preliminary experiments. BM from apoE −/− or DKO mice was transferred to the recipient mice. The recipient mice were allowed to recover for 3 weeks before they were fed high-fat diet for 12 weeks. At the end of investigation, recipient BM DNA was extracted for genotyping of the BM transplanted mice to evaluate the success of the transplantation.
Every mouse was weighed, and the levels of triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein were determined. Atherosclerotic lesion size was quantified by staining the thoracoabdominal aortas and aortic roots with Oil Red O, as described. 9 The thoracoabdominal aorta was opened longitudinally along the ventral midline. Lesion size was assessed by computerized image analysis, and the percentage of lipid deposition was calculated by dividing the stained area by the total thoracoabdominal aortic surface. The atherosclerotic lesion areas of the aortic roots were measured in 8 micron transversal sections through the heart and aortic roots. For each aortic root, the average lesion size was calculated from 3 sections separated from each other by 48 µmol/L. All animal research was approved by the Shanghai Jiao Tong University School of Medicine Animal Care and Use Committee.
Masson Trichrome Staining
Mouse aortic root sections were fixed with Bouin fluid for 1 hour at 56°C, and washed in tap water to remove the yellow color. The sections were stained with Weigert's iron hematoxylin, washed in tap water, and rinsed with distilled water. Sections were placed sequentially into solution A (0.5% acid fuchsin, 0.5% xylidine ponceau, 1% glacial acetic acid) for 10 minutes and then in solution B (1% phosphomolybdic acid) for 5 minutes, and solution C (2% light green SF yellowish, 2% glacial acetic acid) for 5 minutes. Then, the sections were rinsed with distilled water, dehydrated with ethanol, cleared with xylene, and mounted using a resinous medium. Slides were observed under a microscope, and the collagen appeared green. Fibrous content was assessed by computerized image analysis, and the percentage of fibrous content was calculated by dividing the total aortic roots surface.
Indirect Immunofluorescence
Aortic root sections were prepared and fixed in 10% formalin for 10 minutes at room temperature. After 3 washes with PBS, blocking buffer (10% normal goat serum in PBS) was added to the slides, and the slides were incubated at room temperature for at least 2 hours. After removal of the blocking buffer, the monocyte/macrophage marker antibody (Serotech, Raleigh, NC) or the MAC-3 antibody (BD Pharmingen, San Jose, CA) diluted in blocking buffer were added, and the slides were kept in a moisturized box at 4°C overnight. Then the primary antibody was removed, and slides were washed 3× with PBS before fluorescein isothiocyanate-conjugated secondary antibody was added. After incubation for 2 hours at room temperature, the slides were washed 3× with PBS and stained with 4',6-diamidino-2-phenylindole to visualize nuclei, using a fluorescence microscope.
Platelet Preparation and Treatment
Blood was collected from mice anesthetized by intraperitoneal injection of pentobarbital, and washed platelets prepared as described. 21 Platelets were suspended in modified Tyrode's buffer (12-mmol/L NaHCO 3 , 138-mmol/L NaCl, 5.5-mmol/L glucose, 2.9-mmol/L KCl, 2-mmol/L MgCl 2 , 0.42-mmol/L NaH 2 PO 4 , 10-mmol/L HEPES, pH 7.4). Platelet aggregation was performed in a Chrono-Log aggregometer (Chrono-Log, Havertown, PA) at 37°C with stirring at 1200 rpm. ADP (40 µmol/L; Sigma-Aldrich, St. Louis, MO), 2 µg/mL collagen (Nycomed Arzneimittel, Zurich, Switzerland), 0.1 U thrombin (Enzyme Research Laboratories, South Bend, IN), 12 µmol/L protein kinase A (PKA) inhibitor (PKI; calbiochem), respectively were used to activate the platelets, and aggregation was allowed for 3 minutes before the platelets were removed and the supernatant fractions collected for further experiments.
Platelet P-Selectin Expression Assay
One hundred microliters of washed platelets from wild-type (WT) and P2y12 −/− mice, respectively were treated with 0.1 U thrombin for 3 minutes, incubated with fluorescein isothiocyanate-conjugated anti-mouse P-selectin antibody (BD Pharmingen) for 30 minutes at 37°C, and fixed by adding formaldehyde (2% final concentration). P-selectin expression was analyzed using a flow cytometer.
ELISA for Platelet Factor 4
For measuring platelet factor 4 (PF4) levels in mouse plasma, anticoagulated blood was withdrawn from the abdominal aorta of an anesthetized mouse and platelet-poor plasma prepared by centrifugation. The PF4 levels of the platelet-poor plasma were determined by ELISAs according to the manufacturer's directions (R&D Systems, Minneapolis, MN).
Monocyte Chemotaxis Assay
Mouse monocytes were isolated from BM using the tendency of monocyte to adhere rapidly to tissue culture dishes. Briefly, BM was collected from mouse femoral bones, and mononuclear cells were purified using Ficoll. Mononuclear cells were then incubated in Petri dishes for 2 hours, and then the medium was removed and the cells adherent to the plates were treated with a labeled monocyte/macrophage marker antibody, and monocyte purity was evaluated using e83 flow cytometry (mainly monocytes, >80% purity; Figure VI in the online-only Data Supplement). Monocytes suspended in Roswell Park Memorial Institute medium 1640 were added to the upper compartment of the Transwell chambers (Millipore, 5 micron pore size, 0.8 million cells for each chamber). Tyrode's buffer (vehicle control) or supernatant fractions from resting platelets (resting control) or agonist-treated platelets were added into the lower compartment (1:10 dilution into Roswell Park Memorial Institute 1640 medium). In some cases, 20 µg/mL of rat anti-PF4 antibody (R&D) or 20 µg/mL of a control IgG (normal rat IgG; Santa Cruz Biotechnology, Santa Cruz, CA) was added to the lower chamber. After 3 hours of incubation at 37°C 5% CO 2 , the number of cells in the lower compartment was quantified using a hemocytometer.
Statistical Analysis
In all cases, the results from at least 3 independent experiments were used to calculate the mean±SD. Student t test was used for statistical analysis, and P<0.05 was considered statistically significant.
Results
P2Y12 Deficiency Reduces Atherosclerosis in ApoE −/− Mice on High-Fat Diet
To directly assess the role of P2Y12 in diet-induced atherosclerosis, we examined atherosclerotic lesion development in apoE −/− mice with or without P2Y12. ApoE −/− and P2y12 −/−14 mice, both in the C57BL/6 background, were mated with each other, and the resultant apoE +/-P2y12 +/mice were intercrossed to generate the apoE −/− P2y12 +/+ (apoE −/− ) and apoE −/− P2y12 −/− (DKO) offspring required for our experimentation. Genotyping was done by polymerase chain reaction analysis. P2Y12 deficiency was also confirmed by examination of the response of the platelets to ADP, collagen, and thrombin, respectively ( Figure I in the online-only Data Supplement). Both male and female mice were fed a high-fat diet for 20 weeks after weaning, and both apoE −/− and DKO mice gained similar amounts of weight ( Figure 1A ). Then, atherosclerotic lesion development was evaluated by en face analysis of the ratios of lesion areas to the total areas for the aortic arches and the abdominal aortas, respectively, as described in Methods. Compared with apoE −/− mice, the atherogenic areas were significantly less in DKO mice. Analyses of the aortic arch lesion areas expressed as percentages of the total gave mean values (±SD) for male apoE −/− and DKO mice of 33.3±6.1% and 12.6±8.9%, respectively (P<0.01; n=8 for both groups; Figure 1A ). Analyses of the abdominal aorta lesion areas gave mean values (±SD) for male apoE −/− and DKO mice of 12.5±5.6% and 5.1±3.5%, respectively (P<0.05; n=8 for both groups; Figure 1A ). The lesion areas in the aortic arches and the abdominal aortas were diminished by ≈60% in the DKO mice. After the aortic roots of male mice were sectioned and lesion areas assessed, we found that the mean aortic root lesion size was significantly reduced in the DKO mice from 102.2±35.6×10 3 µm 2 in the apoE −/− mice to 21.8±8.3×10 3 µm 2 in DKO mice (P<0.01; Figure 1B ). Furthermore, when we analyzed the atherosclerotic lesions in female mice, there were no significant differences in the lesion formation patterns between male and female mice. Specifically, the results showed that the atherogenic lesions were also significantly reduced in female DKO mice compared with female apoE −/− mice ( Figure 1A ; n=8 for both groups). Thus, P2Y12 deficiency caused a significant reduction of atherosclerotic lesion areas in the aortic arch, the thoracic-abdominal aorta, and the aortic root in apoE −/− mice.
We also analyzed the integrity and thickness of plaque fibrous content (collagen) in male mice because plaque fibrous content is inversely related to the vulnerability of atherosclerotic plaque to rupture. 22 To study the stability of the plaques, Masson trichrome staining of aortic root sections was performed using material from both strains. The data show increased fibrous content and preserved fiber integrity in the plaque of male DKO mice (53.4±7.4%; Figure 1C ) in contrast to that of the male apoE −/− mice (16.9±7.1%; P<0.01). The data suggest that P2Y12 deficiency stabilized plaques, and presumably decreased their tendency to rupture by decreasing their lipid content and increasing their fibrous content. Taken together, these data indicate that P2Y12 apparently modulates the development of atherosclerosis in a manner other than its well-known role in regulating platelet aggregation.
P2Y12 in Platelets Contributes to Atherogenesis
Early studies demonstrated that the P2y12 gene is expressed in a variety of organs and tissues, with the highest expression levels in the brain and platelets. 12 More recently, several studies showed that P2Y12 is also expressed in vascular SMCs. 23, 24 We examined the expression levels of P2Y12 in platelets, peripheral white blood cells (WBC), and aortic SMCs using quantitative real-time reverse transcription polymerase chain reaction to confirm the expression of P2Y12 in SMCs and evaluate P2Y12 expression in nonplatelet white cells. The results were unambiguous, and they demonstrated a much weaker expression of P2Y12 in aortic SMCs than in platelets (≈7% of P2Y12 level in platelets), and almost no expression of P2Y12 in peripheral blood white cells (≈0.5% of P2Y12 level in platelets; Figure II in the online-only Data Supplement). Therefore, it is clear that platelets are the most abundant source of P2Y12 in circulating blood, and that relative to platelets, the level of P2Y12 expression in SMCs is modest.
BM transplantation experiments were performed to further elucidate the contribution of platelet P2Y12 to atherogenesis. Male DKO mice were lethally irradiated and transplanted with DKO (apoE −/− P2y12 −/− ), apoE −/− (apoE −/− P2y12 +/+ ), P2y12 −/− (apoE +/+ P2y12 −/− ), or WT (apoE +/+ P2y12 +/+ ) BM, respectively. After recovery for 3 weeks, the repopulated mice were fed a high-fat diet for 12 weeks. We examined atherosclerosis of aortas and aortic root sections by Oil Red O staining. The results showed that mice receiving P2y12 −/− or WT BM had little plaque formation, presumably because of the apoE secreted by the apoE +/+ macrophages ( Figure IIIA in the onlineonly Data Supplement). 25 However, male mice receiving apoE −/− or DKO BM developed obvious atherosclerotic lesions, and analyses of the lesion area ratios of the aortic arches gave the values of 23.3±7.4% and 4.9±1.3% (P<0.01; n=8 for both groups) for recipients of apoE −/− and DKO BM, respectively (Figure 2A) . Analyses of the abdominal aorta lesion area ratios in the mice that received apoE −/− and DKO BM, respectively gave the corresponding values of 8.8±5.4% and 2.3±0.3% (P<0.01; n=8 for both groups; Figure 2A ), a ≈75% reduction of lesion size in both the aortic arch and the abdominal aorta in the recipients of DKO BM. Lesion sizes of the aortic root sections were significantly reduced in the recipients of the DKO BM, as well ( Figure 2B ). Furthermore, the recipients of the DKO BM had greater fibrous content and integrity of fibers in their plaques than did the recipients of apoE −/− ( Figure 2C ). Genotyping of BM cells retrieved from both groups indicates successful BM transplantation, although there was still some weak expression of the P2Y12 KO allele in apoE −/− BM recipient, which means that 100% replacement of the recipient BM did not occur ( Figure IIIB in the onlineonly Data Supplement). These results demonstrate that platelet P2Y12 contributes to atherogenesis but do not exclude a role for SMC P2Y12 in the process.
Because the peripheral WBC contributes to the progression of inflammation, we determined the WBC counts in apoE −/− BM and DKO BM recipients, after repopulation of the marrows. The WBC counts revealed no significant differences in peripheral WBC counts between the 2 groups ( Figure IIIC in the online-only Data Supplement). Also, flow cytometry analysis with anti-F4/80, anti-CD115, and anti-Ly-6c antibodies (BD Pharmingen) showed similar monocyte frequencies (against total WBC; Figure IVB in the online-only Data Supplement) and inflammatory monocyte (Ly-6C high monocyte) percentages in both transplant groups ( Figure IVA and IVC in the online-only Data Supplement). 2 Collectively, our data demonstrate an important role of platelet P2Y12 in atherosclerotic lesion development.
P2Y12 Deficiency Leads to Less Monocyte/ Macrophage Intima Infiltration
Because monocytes/macrophages are recruited to the ruptured or activated endothelium, and infiltrate the intima and are among the major inflammatory cells that drive atherosclerosis development, 2 we studied monocyte/macrophage vascular intima infiltration as a function of the presence and absence of P2Y12. Using an antibody specific for monocytes and Figure 3 ). To confirm these results, another antibody that specifically recognizes macrophages, MAC-3, was used in the immunofluorescence assays of samples from apoE −/− mice and DKO mice, and we found no obvious difference between monocyte/macrophage marker antibody and MAC-3 antibody staining patterns ( Figure V in the online-only Data Supplement). These results demonstrate that platelet P2Y12 appears to play an important role in monocyte/macrophage infiltration at the plaque site.
P2Y12 Deficiency Has No Effect on Lipid Profiles But Affects Levels of Inflammatory Cytokines
Having observed that P2Y12 deficiency in apoE −/− mice had a protective effect against diet-induced atherosclerosis, we evaluated the underlying mechanisms. Considering that high levels of low-density lipoprotein and cholesterol are the principal causes of atherosclerosis, we first examined the blood levels of total cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein in male apoE −/− and DKO mice. The total cholesterol and triglyceride levels of the apoE −/− and DKO mice were similar ( Table I in Table I in the online-only Data Supplement). These findings demonstrated that loss of P2Y12 did not affect the hypercholesterolemia in apoE-deficient mice induced by the high-fat diet, and therefore was not a mechanism underlying diminished atherosclerosis development in DKO mice.
Another factor we considered was secretion of the proinflammatory cytokines and chemokines from platelets into the blood on platelet activation. Platelet α-granules contain various kinds of proinflammatory cytokines and factors. 26 Among them is PF4 (PF4/chemokine [C-X-C motif] ligand 4), a platelet-specific chemokine released from α-granules which has a chemotactic effect on leukocytes, and has been localized to atherosclerotic lesions. 27, 28 Also, PF4 can induce a monocyte oxidative burst and elicit monocyte invasion at plaque sites. 29 We found that plasma levels of PF4 in male DKO mice were markedly lower than in male apoE −/− mice (P<0.01; n=8 for both groups; Figure 4A ). In the BM transplantation groups, the average plasma level of PF4 was 47.7±18 ng/mL in apoE −/− BM recipients compared with 9.9±5.4 ng/mL in DKO BM recipients (P<0.01; n=8 for both groups; Figure 4B ). These data demonstrate that the lower levels of PF4, and probably other cytokines or chemokines (eg, regulated on activation, normal T cell) derived from platelets, might be at least 
P2Y12 Regulates Platelet α-Granule Release
Because our data suggest a role of P2Y12 in regulating platelet α-granule release, WT and P2y12 −/− platelets were stimulated with a low level of each of the agonists ADP, collagen, and thrombin to evaluate this function of P2Y12 in vitro. The agonists induced substantial PF4 release from the α-granules of the WT platelets; in contrast, P2Y12 deficiency almost completely suppressed PF4 release in response to agonist treatment ( Figure 5A ). Also, P2Y12 absence eliminated expression of P-selectin on platelets stimulated by low level of thrombin ( Figure 5C ). P-selectin is an indicator of platelet α-granule release and an important mediator in atherosclerosis. 10 The results of chemotaxis assays demonstrated that the supernatant fluids obtained from WT platelets after stimulation by a low level of one of each agonist induced significantly more monocytes to migrate than did the supernatant fluids from resting platelets, and from stimulated P2y12 −/− platelets, respectively. Finally, an anti-PF4 antibody in the supernatant fluids from WT platelets stimulated by a low level of collagen eliminated or nearly eliminated the ability of the supernatant fluids to stimulate monocyte migration ( Figure 6A and 6B) . Taken together, these data provide evidence that during platelet activation, P2Y12 regulates α-granule release, thereby affecting secretion of plateletderived inflammatory factors such as PF4 and recruitment of monocytes to the vascular wall.
P2Y12 Regulates α-Granule Release Through Inhibition of cAMP-PKA Pathway
ADP receptor P2Y12 is a G protein-coupled receptor that activates Gi in response to ligand binding. Specifically, activation of Gi in response to ligand binding inhibits the activity of adenylyl cyclase leading to a decreased cytoplasmic concentration of cAMP, diminished activation of cAMPdependent PKA, and a resultant increase of platelet activation and secretion. 12 Platelets express several other Gi-coupled receptors such as the α2A-adrenergic, platelet activating factor 1, lysophosphatidic acid, and C-X-C chemokine receptor type 4 receptors. 30 These receptors may also regulate platelet α-granule release, and thereby affect atherosclerosis. To evaluate the role of cAMP-PKA pathway in α-granule release, the PKI was used. In response to PKI treatment, large quantities of PF4 were released from both WT and P2Y12deficient platelets ( Figure 5B ). Also, P-selectin was expressed on both WT and P2Y12-deficient platelets in response to PKI treatment, expressing even greater levels than platelets treated with thrombin ( Figure 5C ). Supernatant fluid from WT platelets or P2Y12-deficient platelets treated with PKI also induced more monocyte migration than the releasate of resting platelets ( Figure 6C ). These results demonstrate that inhibition of PKA activity is able to cause platelet α-granule release and therefore may have a similar effect on atherosclerosis as P2Y12.
Discussion
Here, we report a previously unknown critical modulating role of P2Y12 in the formation of atherosclerotic lesions in apoE −/− mice and present the molecular mechanism underlying P2Y12-dependent atherogenesis. Our data challenge the traditional view of P2Y12 as just a regulator of platelet activation and aggregation by identifying P2Y12 as a modulator of atherosclerosis. We propose that the mechanism of this modulation is the regulation of the release of proinflammatory factors from platelet α-granules by P2Y12. Characterization of this function of P2Y12 may justify the clinical use of P2Y12 antagonists to prevent vascular inflammation and atherogenesis.
Atherosclerosis is the leading cause of death in the world, which has promoted an enormous campaign to search for effective antithrombotic agents to prevent events such as myocardial infarction, stroke, and peripheral vascular disease. P2Y12 antagonists such as clopidogrel proved to be efficacious for the prevention of atherothrombotic events and are Figure 5 . Purinergic receptor P2Y, G protein-coupled 12 (P2Y12) regulates platelet α-granule content release through cAMP protein kinase A (PKA) signaling. Aggregation of 300-μL platelet suspensions was performed in a Chrono-Log aggregometer at 37°C with stirring. Forty moles per liter ADP, 2-μg/mL collagen, or 0.1 U thrombin were added, and 3 minutes later the platelets were removed by centrifugation and the supernatant fluids collected for measuring platelet factor 4 (PF4) concentrations by ELISAs. A, Results were expressed as means±SD. **P<0.01. B, Platelets from wild-type (WT) and P2y12 −/− mice were treated in an aggregometer with PKA inhibitor (PKI; no agonist), and then the PF4 levels in the supernatant fluids were measured by an ELISA assay. Each result is expressed as the mean±SD. **P<0.01. C, Platelets from WT and P2y12 −/− mice were treated with 12-μmol/L PKI or 0.1 U thrombin, and P-selectin expression was assessed by flow cytometry. All experiments were performed 3×, and representative results are shown. Figure 6 . Platelet purinergic receptor P2Y, G protein-coupled 12 (P2Y12) function affects monocyte migration induced by platelet releasates. A and B, Monocytes separated from mouse bone marrow were added to the upper chambers of a Transwell migration apparatus whereas the vehicle control (Tyrode buffer), supernatant fractions of resting platelets (resting control), or platelets treated with 40-μmol/L ADP or 2-μg/mL collagen were added to the bottom chambers (in some cases, 20 μg/mL of a rat antiplatelet factor 4 antibody [PF4 Ab] was included in the lower chamber to inhibit PF4 activity with normal rat IgG being control), as described in Methods section. Cells were allowed to migrate for 3 hours at 37°C before counting the migrated cells. Results are expressed as fold changes of the vehicle group (mean±SD, **P<0.01). C, Twelve moles per liter PKA inhibitor (PKI) was used, instead of a classic platelet agonist to elicit α-granule release (in some cases, 20 μg/mL of an anti-PF4 antibody was included in the lower chamber to inhibit PF4 activity). Results are expressed as fold changes of the vehicle group (mean±SD, **P<0.01). All experiments were performed 3×, and representative results are shown. WT indicates wild-type. widely used. Some researchers who investigated atherosclerosis-related cytokine profiles in patients consuming P2Y12 antagonists made the discovery that clopidogrel treatment was correlated with decreased levels of the inflammatory risk factors such as C-reactive protein, CD40 ligand, and P-selectin in the patients. [16] [17] [18] These studies provided the first clue that links P2Y12 to atherogenesis, apart from its well-established role in platelet activation. Some groups tried to evaluate the effect of clopidogrel on atherosclerosis using murine models. 19, 20 However, the results of those studies were contradictory, leaving the question still unresolved.
To circumvent the disadvantages of using P2Y12 antagonists in our effort to evaluate the role of P2Y12 in inflammation and atherogenesis, we used a genetic murine model. The data presented here demonstrate that P2Y12 modulates atherosclerotic lesion formation by regulating platelet α-granule release. Our results not only show a reduction in total lesion size in DKO mice compared with controls, they also demonstrate that plaques in these mice had histological features, less macrophages, and an increased fibrous content, attributed to more stable plaques. The decreased macrophage number is important because intimal macrophages are the determinants of plaque growth and are associated with thrombotic complications. 3, 31 One of the concerns is whether or not the function of monocytes/macrophages was affected in P2Y12-deficient mice. In light of an earlier study concerning the cellular distribution of P2Y12 32 and our observation that peripheral blood leukocytes do not express P2Y12, it is unlikely that P2Y12 deficiency can directly affect the normal functions of monocytes and macrophages.
In our effort to elucidate the underlying mechanism of P2Y12-mediated atherosclerosis, one of the most significant observations was the decrease of plasma PF4 levels in P2Y12deficient apoE −/− mice or in P2y12 −/− BM recipients. PF4, a platelet-specific chemokine stored in platelet α-granules, has been demonstrated to participate in atherogenesis by affecting monocyte recruitment and adhesion. [9] [10] [11] [33] [34] [35] Given the considerable contribution of PF4 to atherosclerotic lesion development, we could easily infer from our data that the decreased levels of PF4 and other secreted proinflammatory α-granule components are the reasons why P2Y12-deficient apoE −/− mice developed less atherosclerotic lesions than were formed in the control mice. Therefore, our study enhances the cumulative evidence supporting the importance of PF4, and other proinflammatory cytokines and chemokines, in the initiation and development of atherosclerosis.
The expression of P2Y12 has also been documented in vascular SMCs, although the level is much lower than in platelets. In our transplantation experiments, we used DKO mice as recipients to exclude the possible complication caused by SMC P2Y12 in the recipient mice. Although we can conclude that platelet P2Y12 plays a part in atherogenesis, our experiments do not exclude a role for SMC P2Y12 in this process. Resolution of this issue requires the use of promoter-specific P2Y12 KO strategies and the systematic analysis of the contributions to atherogenesis of P2Y12 in both platelets and SMCs. This work is beyond the scope of the present study. Nonetheless, regardless of the contribution of P2Y12 from cells other than platelets, the data demonstrate unambiguously that P2Y12 modulates atherogenesis in vivo and provide a rationale for the clinical use of P2Y12 antagonists to prevent atherosclerosis.
Apart from P2Y12, platelets express several other Gi-coupled receptors 36 that modulate signaling by lowering the levels of cAMP and thereby decrease PKA activity. To provide further support to our theory and characterize the role of PKA in platelet activation, we examined the effect of a PKI on platelet α-granule release. The PKI caused extensive α-granule content release, highlighting the critical role of PKA in regulating the balance between the resting and activation states of platelets.
Platelets also have a set of Gs-coupled receptors including the prostacyclin, prostaglandin D2, prostaglandin E2, A2α-adenosine, and β2-adrenergic receptors, which signal to increase adenylyl cyclase activity and keep platelets in a quiescent state. 37 Prostacyclin is released from endothelial cells and binds to the platelet prostacyclin receptor IP. 38 ApoE −/− IP −/− mice exhibited a significant acceleration in atherogenesis compared with apoE −/− IP +/+ mice. 39 These results and the data presented here ( Figure 5A and 5B) support the conclusion that cAMP-PKA signaling is an important regulator of platelet α-granule release and therefore an important causative factor for atherogenesis and justify the view that blocking platelet Gi-mediated signaling may serve as an important therapeutic strategy for the prevention of atherosclerosis.
